Skip Nav Destination
Issues
1 August 2007
-
Cover Image
Cover Image
Epidermal growth factor receptor (EGFR) expression in clear cell sarcoma of the kidney (CCSK; magnification x 200). Screening of a pediatric renal tumour tissue microarray for EGFR expression by immunohistochemistry revealed a striking predilection for CCSK. More detailed investigation of these cases revealed instances of EGFR gene amplification and mutation, as well as mutations in PTEN and downstream pathway activation by means of phosphorylated Akt up-regulation. These data provide evidence for an activated EGFR pathway in these childhood tumours and the possibility of targeted therapeutic intervention. For further details, please see Little and associates on page 4360 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Editorial
The Biology Behind
Molecular Pathways
Review Article
Human Cancer Biology
Imaging, Diagnosis, Prognosis
Emmprin and Survivin Predict Response and Survival following Cisplatin-Containing Chemotherapy in Patients with Advanced Bladder Cancer
Anne B. Als; Lars Dyrskjøt; Hans von der Maase; Karen Koed; Francisco Mansilla; Helle E. Toldbod; Jens L. Jensen; Benedicte P. Ulhøi; Lisa Sengeløv; Klaus M.E. Jensen; Torben F. Ørntoft
External Validation of Mathematical Models to Distinguish Between Benign and Malignant Adnexal Tumors: A Multicenter Study by the International Ovarian Tumor Analysis Group
Caroline Van Holsbeke; Ben Van Calster; Lil Valentin; Antonia C. Testa; Enrico Ferrazzi; Ioannis Dimou; Chuan Lu; Philippe Moerman; Sabine Van Huffel; Ignace Vergote; Dirk Timmerman
Cancer Therapy: Clinical
Phase 1 Study of Lumiliximab with Detailed Pharmacokinetic and Pharmacodynamic Measurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
John C. Byrd; Susan O'Brien; Ian W. Flinn; Thomas J. Kipps; Mark Weiss; Kanti Rai; Thomas S. Lin; James Woodworth; Dee Wynne; Jennifer Reid; Arturo Molina; Bryan Leigh; Sarah Harris
A Phase I Clinical Trial of Single-Dose Intrapleural IFN-β Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses
Daniel H. Sterman; Adri Recio; Richard G. Carroll; Colin T. Gillespie; Andrew Haas; Anil Vachani; Veena Kapoor; Jing Sun; Richard Hodinka; Jennifer L. Brown; Michael J. Corbley; Michael Parr; Mitchell Ho; Ira Pastan; Michael Machuzak; William Benedict; Xin-qiao Zhang; Elaina M. Lord; Leslie A. Litzky; Daniel F. Heitjan; Carl H. June; Larry R. Kaiser; Robert H. Vonderheide; Steven M. Albelda
Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia
Judith E. Karp; B. Douglas Smith; Mark J. Levis; Steven D. Gore; Jacqueline Greer; Catherine Hattenburg; Janet Briel; Richard J. Jones; John J. Wright; A. Dimitri Colevas
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C β-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer
Jeany M. Rademaker-Lakhai; Laurens V. Beerepoot; Niven Mehra; Sandra A. Radema; Rianne van Maanen; Joost S. Vermaat; Els O. Witteveen; Carla M. Visseren-Grul; Luna Musib; Nathan Enas; Gertjan van Hal; Jos H. Beijnen; Jan H.M. Schellens; Emile E. Voest
Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients
Daniele Santini; Bruno Vincenzi; Sara Galluzzo; Fabrizio Battistoni; Laura Rocci; Olga Venditti; Gaia Schiavon; Silvia Angeletti; Federica Uzzalli; Michele Caraglia; Giordano Dicuonzo; Giuseppe Tonini
Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Chemotherapy Induces Potent Immune Responses
Richard Harrop; Noel Drury; William Shingler; Priscilla Chikoti; Irina Redchenko; Miles W. Carroll; Susan M. Kingsman; Stuart Naylor; Alan Melcher; Joanna Nicholls; Harpreet Wassan; Nagy Habib; Alan Anthoney
Phase I Pharmacokinetic Study of the Safety and Tolerability of Lapatinib (GW572016) in Combination with Oxaliplatin/Fluorouracil/Leucovorin (FOLFOX4) in Patients with Solid Tumors
Wandena S. Siegel-Lakhai; Jos H. Beijnen; Walter L. Vervenne; Henk Boot; Marianne Keessen; Melissa Versola; Kevin M. Koch; Deborah A. Smith; Lini Pandite; Dirk J. Richel; Jan H.M. Schellens
Cancer Therapy: Preclinical
The Tyrosine Kinase Inhibitor, AZD2171, Inhibits Vascular Endothelial Growth Factor Receptor Signaling and Growth of Anaplastic Thyroid Cancer in an Orthotopic Nude Mouse Model
Fernando Gomez-Rivera; Alfredo A. Santillan-Gomez; Maher N. Younes; Seungwon Kim; David Fooshee; Mei Zhao; Samar A. Jasser; Jeffrey N. Myers
Synergistic In vivo Antitumor Effect of the Histone Deacetylase Inhibitor MS-275 in Combination with Interleukin 2 in a Murine Model of Renal Cell Carcinoma
Yukihiko Kato; Kiyoshi Yoshimura; Tahiro Shin; Henk Verheul; Hans Hammers; Tolib B. Sanni; Brenda C. Salumbides; Karen Van Erp; Richard Schulick; Roberto Pili
Novel Agents in the Treatment of Lung Cancer
Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference
Thomas J. Lynch; Philip D. Bonomi; Charles Butts; Angela M. Davies; Jeffrey Engelman; Ramaswamy Govindan; Roy S. Herbst; John V. Heymach; Bruce E. Johnson; Renato G. Martins; Roman Perez-Soler; Gregory J. Riely; Alan B. Sandler; Lecia V. Sequist; Mark A. Socinski; Kwok-Kin Wong; Carol S. Hart
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.